NCT00251472

A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Veeda Oncology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer. Each cycle of treatment will be 4 weeks in length. Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.

Conditions

• Metastatic Breast Cancer

Interventions

Type	Name	Description
DRUG	Paclitaxel Albumin Nanoparticle for Injectable Suspension	125mg/m2 by 30-minute IV infusion, once a week.

Timeline

• Start date: 2005-03-01
• Primary completion: 2010-05-01
• Completion: 2010-05-01
• First posted: 2005-11-10
• Last updated: 2012-05-11

Locations

1 site across 1 country: United States